June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket

Published 03/15/2018, 07:30 AM
© Reuters.  Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
ALXN
-
ACHN_old
-
FBIO
-
AKTX
-
RARX_old
-
APLS
-
  • Alexion Pharmaceuticals (NASDAQ:ALXN) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
  • The data showed ALXN1210 to be non-inferior to Soliris (eculizumab) by virtue of achieving the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels, a direct marker of complement-mediated hemolysis in PNH.
  • ALXN1210 also demonstrated non-inferiority to Soliris on all four key secondary endpoints.
  • Detailed results will be submitted for presentation at a future medical conference.
  • ALXN1210 is a long-acting C5 inhibitor that is administered six times per year compared to 26 times per year for Soliris.
  • The company plans to file marketing applications in the U.S., EU and Japan in H2.
  • Management will host a conference call this morning at 8:30 am ET to discuss the results.
  • PNH-related tickers: (NASDAQ:APLS)(NASDAQ:RARX)(NASDAQ:AKTX)(NASDAQ:ACHN)(NASDAQ:FBIO)
  • Now read: Alexion Pharmaceuticals - Appeal Increases, Not Pulling The Trigger Yet


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.